Navigation Links
BioMed Realty Trust Announces Exercise of Over-Allotment Option
Date:10/6/2008

SAN DIEGO, Oct. 6 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced that on October 1, 2008 the underwriter exercised its over-allotment option in full to purchase an additional 1,125,000 shares of common stock in connection with BioMed's previously announced offering that priced on October 1, 2008. In total, the company sold 8,625,000 shares of common stock, raising net proceeds of approximately $212.4 million after deducting underwriter discounts and commissions and estimated expenses. UBS Investment Bank is acting as the sole underwriter for the offering.

The registration statement relating to these securities has become effective by rule of the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of BioMed's common stock, nor shall there be any sale of such common stock in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. The offering of BioMed's common stock is made only by means of a prospectus and a related prospectus supplement, copies of which may be obtained from

UBS Investment Bank

Prospectus Department

299 Park Avenue

New York, NY 10171

or by telephone toll free at 888-827-7275, extension 3884.

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry(R). The company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed Realty Trust owns or has interests in 69 properties, representing 112 buildings with approximately 10.4 million rentable square feet, including approximately 1.9 million square feet of development in progress. The company also owns undeveloped land parcels adjacent to existing properties that it estimates can support up to 1.4 million rentable square feet. The company's properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have well-established reputations as centers for scientific research. Additional information is available at http://www.biomedrealty.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associated with the availability and terms of financing and the use of debt to fund acquisitions and developments; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; risks and uncertainties affecting property development and construction; risks associated with downturns in the national and local economies, increases in interest rates, and volatility in the securities markets; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMed Realty Trust, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
2. BioMed Realty Trust Declares Third Quarter 2007 Common Stock and Preferred Stock Dividends
3. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
4. Verax Biomedical Receives 510 (k) Clearance from FDA for Platelet PGD Test
5. SLIM Search, Inc. Sponsors Next Generation Sequencing Conference for the Biomedical Market
6. NCIIA Announces Launch of 4th Annual Student Biomedical Innovation Competition
7. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
8. Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal
9. Crux Biomedical Announces First Successful U.S. Implant of Its New Retrievable Inferior Vena Cava (IVC) Filter
10. Environmental Tectonics Corporations BioMedical Division Announces New Contract
11. Avery Biomedical Devices, Inc. Appoints Elefteriades to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... , Dec. 3, 2016  In five studies ... Hematology (ASH) Annual Meeting and Exposition in ... engineering methods to improve the delivery of life-saving treatments ... new methods are designed to carry therapies directly to ... most, which could provide a substantial advantage over traditional, ...
(Date:12/2/2016)... Calif. , Dec. 2, 2016 Amgen (NASDAQ: ... AGN ) today announced the submission of a Marketing Authorization ... 215, a biosimilar candidate to Avastin ® (bevacizumab). The ... submitted to the EMA. "The submission of ... Amgen seeks to expand our oncology portfolio," said Sean ...
(Date:12/2/2016)... ... December 01, 2016 , ... Aerocom ... North American hospitals, will present its chain-of-custody solution for tracking and securing medications ... Vegas, Nev., Dec. 4-8, 2016. , Aerocom has a proven solution for tracking ...
(Date:12/2/2016)... DC (PRWEB) , ... December ... ... Consortiumâ„¢ (ETC), a consortium of pharmaceutical and biotechnology companies dedicated to collaboratively ... seeking companies interested in supplying a vendor-supported, portable online UHPLC, with robust, ...
Breaking Biology Technology:
(Date:11/15/2016)... , Nov 15, 2016 Research and ... Global Forecast to 2021" report to their offering. ... ... USD 16.18 Billion by 2021 from USD 6.21 Billion in 2016, ... Growth of the bioinformatics market is driven by the ...
(Date:6/27/2016)... Research and Markets has announced the addition of the ... offering. The report forecasts the ... at a CAGR of 12.28% during the period 2016-2020. ... analysis with inputs from industry experts. The report covers the market ... also includes a discussion of the key vendors operating in this ...
(Date:6/22/2016)... On Monday, the Department of Homeland Security (DHS) issued ... the Biometric Exit Program. The Request for Information (RFI), ... that CBP intends to add biometrics to confirm when ... , in order to deter visa overstays, to ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
Breaking Biology News(10 mins):